Mostrando reg. 1 a 19 de 19
| Fecha de Publicación | Título | Autor(s) |
| 2016 | Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy | TEMPLETON, ARNOUD J.; KNOX, JENNIFER J.; LIN, XUN, etc. |
| 2017 | Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials | MOREIRA, RAPHAEL B.; Marcio Debiasi; FRANCINI, EDOARDO, etc. |
| 2017 | Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials | MOREIRA, RAPHAEL B.; Marcio Debiasi; FRANCINI, EDOARDO, etc. |
| 2015 | Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma | ALBIGES, LAURENCE; André Poisl Fay; XIE, WANLING, etc. |
| 2017 | ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis | URUN, YUKSEL; LEOW, JEFFREY J.; André Poisl Fay, etc. |
| 2015 | HER2 as a target in invasive urothelial carcinoma | BELLMUNT, JOAQUIM; WERNER, LILLIAN; BAMIAS, ARISTOTLE, etc. |
| 2015 | HER2 as a target in invasive urothelial carcinoma | BELLMUNT, JOAQUIM; WERNER, LILLIAN; BAMIAS, ARISTOTLE, etc. |
| 2018 | Impact of Geographic Regions on Overall Survival in Patients With Metastatic Renal Cell Carcinoma: Results From an International Clinical Trials Database | André Poisl Fay; MCKAY, RANA R.; LIN, XUN, etc. |
| 2018 | Impact of Geographic Regions on Overall Survival in Patients With Metastatic Renal Cell Carcinoma: Results From an International Clinical Trials Database | André Poisl Fay; MCKAY, RANA R.; LIN, XUN, etc. |
| 2017 | Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model | DE VELASCO, GUILLERMO; CULHANE, AEDÍN C.; André Poisl Fay, etc. |
| 2019 | Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma | NASSAR, AMIN H; HAMIEH, LANA; GRAY, KATHRYN P., etc. |
| 2016 | Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma | DE VELASCO, GUILLERMO; GRAY, KATHRYN P.; HAMIEH, LANA, etc. |
| 2016 | Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma | DE VELASCO, GUILLERMO; GRAY, KATHRYN P.; HAMIEH, LANA, etc. |
| 2016 | Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma | MAHONEY, KATHLEEN M.; JACOBUS, SUSANNA; BHATT, RUPAL S., etc. |
| 2015 | Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors | BELLMUNT, JOAQUIM; WERNER, LILLIAN; LEOW, JEFFREY J., etc. |
| 2015 | Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors | BELLMUNT, JOAQUIM; WERNER, LILLIAN; LEOW, JEFFREY J., etc. |
| 2016 | Statins and survival outcomes in patients with metastatic renal cell carcinoma | MCKAY, RANA R.; LIN, XUN; ALBIGES, LAURENCE, etc. |
| 2018 | The Clinical Activity of PD-1/PD-L1 inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma | MCKAY, RANA R.; BOSSÉ, DOMINICK; XIE, WANLING, etc. |
| 2018 | The Clinical Activity of PD-1/PD-L1 inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma | MCKAY, RANA R.; BOSSÉ, DOMINICK; XIE, WANLING, etc. |
